Camras CB, Neely DG, Weiss EL. Latanoprost-induced iris color darkening: a case report with long-term follow-up. J Glaucoma. 2000;9:95-98. Yamamoto T, Kitazawa Y. Iris-color change developed after topical isopropyl unoprostone treatment. J Glaucoma. 1997;6:430-432.

Zhan GL, Toris CB, Meza JL, Camras CB. Unoprostone isopropyl ester darkens iris color in pigmented rabbits with sympathetic denervation. J Glaucoma. 2003;12:383-389.

Albert DM, Gangnon RE, Zimbric ML, et al. A study of iridectomy histopathologic features of latanoprost- and non-latanoprost-treated patients. Arch Ophthalmol. 2004; 122:1680-1685.

Grierson I, Pfeiffer N, Cracknell KPB, Appleton P. Histology and fine structure of the iris and outflow system following latanoprost therapy. Surv Ophthalmol. 2002; 47(suppl 1):S176-S184.

Cracknell KP, Grierson I, Hogg P, et al. Latanoprost-induced iris darkening: a mor-phometric study of human peripheral iridectomies. Exp Eye Res. 2003;77:721-730. Pfeiffer N, Grierson I, Goldsmith H, et al. Fine structural evaluation of the iris after unilateral treatment with latanoprost in patients undergoing bilateral trabeculectomy (the Mainz II study). Arch Ophthalmol. 2003;121:23-31.

Nakamura Y, Nakamura Y, Morine-Shinjo S, et al. Assessment of chamber angle pigmentation during longterm latanoprost treatment for open-angle glaucoma. Acta Ophthalmol. 2004;82:158-160.

Cracknell KP, Grierson I, Hogg P, et al. Melanin in the trabecular meshwork is associated with age, POAG but not latanoprost treatment. A masked morphometric study. Exp Eye Res. 2006;82:986-993.

Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol. 1997;124:544-547.

Johnstone MA, Albert DM. Prostaglandin-induced hair growth. Surv Ophthalmol. 2002;47(suppl 1):S185-S202.

Packer M, Fine IH, Hoffman RS. Bilateral nongranulomatous anterior uveitis associated with bimatoprost. J Cataract Refract Surg. 2003;29:2242-2243. Parentin F. Granulomatous anterior uveitis associated with bimatoprost: a case report. Ocul Immunol Inflamm. 2003;11:67-71.

Suominen S, Valimaki J. Bilateral anterior uveitis associated with travoprost. Acta Ophthalmol. 2006;84:275-276.

Kumarasamy M, Desai SP. Anterior uveitis is associated with travoprost. BMJ. 2004;329:205.

Martin E, Martinez-de-la-Casa JM, Garcia-Feijoo J, et al. A 6-month assessment of bimatoprost 0.03% vs timolol maleate 0.5%: hypotensive efficacy, macular thickness and flare in ocular-hypertensive and glaucoma patients. Eye 2007;21:164-168. Cellini M, Caramazza R, Bonsanto D, et al. Prostaglandin analogs and blood-aqueous barrier integrity: a flare cell meter study. Ophthalmologica. 2004;218:312-317. Carrillo MM, Nicolela MT. Cystoid macular edema in a low-risk patient after switching from latanoprost to bimatoprost. Am J Ophthalmol. 2004;137:966-968. Wand M, Gaudio AR. Cystoid macular edema associated with ocular hypotensive lipids. Am J Ophthalmol. 2002;133:403-405.

Yeh PC, Ramanathan S. Latanoprost and clinically significant cystoid macular edema after uneventful phacoemulsification with intraocular lens implantation. J Cataract Refract Surg. 2002;28:1814-1818.

Camras CB. CME and anterior uveitis with latanoprost use. Ophthalmology. 1998;105:1978-1981.

Camras CB, Bhuyan KC, Podos SM, et al. Multiple dosing of prostaglandin F2a or epinephrine on cynomolgus monkey eyes. II. Slit-lamp biomicroscopy, aqueous humor analysis, and fluorescein angiography. Invest Ophthalmol Vis Sci. 1987;28: 921-926.

Hoyng PFJ, Rulo AH, Greve EL, et al. Fluorescein angiographic evaluation of the effect of latanoprost treatment on blood-retinal barrier integrity: a review of studies conducted on pseudophakic glaucoma patients and on phakic and aphakic monkeys. Surv Ophthalmol. 1997;41(suppl 2):S83-S88.

Miyake K, Ibaraki N, Goto Y, et al. ESCRS Binkhorst lecture 2002: Pseudophakic preservative maculopathy. J Cataract Refract Surg. 2003;29:1800-1810. Herndon LW, Robert DW, Wand M, Asrani S. Increased periocular pigmentation with ocular hypotensive lipid use in African Americans. Am J Ophthalmol. 2003;135:713-715.

Kapur R, Osmanovic S, Toyran S, Edward DP. Bimatoprost-induced periocular skin hyperpigmentation: histopathological study. Arch Ophthalmol. 2005;123:1541-1546. Peplinski LS, Albiani SK. Deepening of lid sulcus from topical bimatoprost therapy. Optom Vis Sci. 2004;81:574-577.

Gordon YJ, Yates KA, Mah FS, Romanowski EG. The effects of Xalatan on the recovery of ocular herpes simplex virus type 1 (HSV-1) in the induced reactivation and spontaneous shedding rabbit models. J Ocul Pharmacol Ther. 2003;19:233-245. Bean G, Reardon G, Zimmerman TJ. Association between ocular herpes simplex virus and topical ocular hypotensive therapy. J Glaucoma. 2004;13:361-364. Inan UU, Ermis SS, Orman A, et al. The comparative cardiovascular, pulmonary, ocular blood flow, and ocular hypotensive effects of topical travoprost, bimatoprost, brimonidine, and betaxolol. J Ocul Pharmacol Ther. 2004;20:293-310.

81. Hedman K, Larsson LI. The effect of latanoprost compared with timolol in African-American, Asian, Caucasian, and Mexican open-angle glaucoma or ocular hypertensive patients. Surv Ophthalmol. 2002;47(suppl 1):S77-S89.

82. O'Donoghue EP. A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3 month, randomised study. Br J Ophthalmol. 2000;84:579-582.

83. Kimal Arici M, Topalkara A, Guler C. Additive effect of latanoprost and dorzolamide in patients with elevated intraocular pressure. Int Ophthalmol. 1998;22:37-42.

84. Day DG, Sharpe ED, Beischel CJ, et al. Safety and efficacy of bimatoprost 0.03% versus timolol maleate 0.5%/dorzolamide 2% fixed combination. Eur J Ophthalmol. 2005;15:336-342.

85. Coleman AL, Lerner F, Bernstein P, Whitcup SM. A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension. Ophthalmology. 2003;110:2362-2368.

86. Chiselita D, Antohi I, Medvichi R, Danielescu C. Comparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol-dorzolamide; a prospective, randomized, masked, cross-over design study. Oftalmologia. 2005;49: 39-45.

87. Fechtner RD, McCarroll KA, Lines CR, Adamsons IA. Efficacy of the dorzolamide/ timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studies. J Ocul Pharmacol Ther. 2005;21:242-249.

88. Camras CB, Sheu WP. Latanoprost or brimonidine as treatment for elevated intraocular pressure: multicenter trial in the United States. J Glaucoma. 2005;14:161-167.

89. Camras CB. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2002;133:732.

90. Netland PA, Robertson SM, Sullivan EK, et al. Response to travoprost in black and nonblack patients with open-angle glaucoma or ocular hypertension. Adv Ther. 2003;20:149-163.

91. Higginbotham EJ, Diestelhorst M, Pfeiffer N, et al. The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications. Surv Ophthalmol. 2002;47(suppl 1):S133-S140.

92. Toor A, Chanis RA, Polikoff LA, et al. Additivity of pilocarpine to bimatoprost in ocular hypertension and early glaucoma. J Glaucoma. 2005;14:243-248.

93. Netland PA, Michael M, Rosner SA, et al. Brimonidine purite and bimatoprost compared with timolol and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 2003;20:20-30.

94. Hughes BA, Bacharach J, Craven ER, et al. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension. J Glaucoma. 2005;14:392-399.

95. Schuman JS, Katz GJ, Lewis RA, et al. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2005;140:242-250.

96. Barnebey HS, Orengo-Nania S, Flowers BE, et al. The safety and efficacy of travo-prost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am J Ophthalmol. 2005;140:1-7.

Diestelhorst M, Larsson LI. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology. 2006;113:70-76.

Hamacher T, Schinzel M, Scholzel-Klatt A, et al. Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies. Br J Ophthalmol. 2004; 88:1295-1298.

Gandolfi SA, Rossetti L, Cimino L, et al. Replacing maximum-tolerated medications with latanoprost versus adding latanoprost to maximum-tolerated medications: a two-center randomized prospective trial. J Glaucoma. 2003;12:347-353. Rulo AH, Greve EL, Hoyng PFJ. Additive ocular hypotensive effect of latanoprost and acetazolamide. A short-term study in patients with elevated intraocular pressure. Ophthalmology. 1997;104:1503-1507.

O'Connor DJ, Martone JF, Mead A. Additive intraocular pressure lowering effect of various medications with latanoprost. Am J Ophthalmol. 2002;133:836-837. Akman A, Cetinkaya A, Akova YA, Ertan A. Comparison of additional intraocular pressure-lowering effects of latanoprost vs brimonidine in primary open-angle glaucoma patients with intraocular pressure uncontrolled by timolol-dorzolamide combination. Eye. 2005;19:145-151.

Martinez-de-la-Casa JM, Castillo A, Garcia-Feijoo J, et al. Concomitant administration of travoprost and brinzolamide versus fixed latanoprost/timolol combined therapy: three-month comparison of efficacy and safety. Curr Med Res Opin. 2004; 20:1333-1339.

Reis R, Queiroz CF, Santos LC, et al. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension. Clin Ther. 2006;28:552-559. Toris CB, Zhan GL, Zhao J, et al. Potential mechanism for the additivity of pilocarpine and latanoprost. Am J Ophthalmol. 2001;131:722-728. Camras CB, Feldman SG, Podos SM, et al. Inhibition of the epinephrine-induced reduction of intraocular pressure by systemic indomethacin in humans. Am J Oph-thalmol. 1985;100:169-175.

Erdogan H, Toker I, Arici MK, et al. A short-term study of the additive effect of latanoprost 0.005% and brimonidine 0.2%. Jpn J Ophthalmol. 2003;47:473-478.

Konstas AG, Karabatsas CH, Lallos N, et al. 24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects. Ophthalmology. 2005;112:603-608.

Stewart WC, Stewart JA, Day DG, et al. Efficacy and safety of the latanoprost/timolol maleate fixed combination vs concomitant brimonidine and latanoprost therapy. Eye. 2004;18:990-995.

Higginbotham EJ, Feldman R, Stiles M, et al. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol. 2002;120: 915-922.

Pfeiffer N. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol. 2002;240:893-899. Konstas AG, Boboridis K, Tzetzi D, et al. Twenty-four-hour control with latano-prost-timolol-fixed combination therapy vs latanoprost therapy. Arch Ophthalmol. 2005;123:898-902.

113. Konstas AG, Banyai L, Blask KD, et al. Intraocular pressure and safety in glaucoma patients switching to latanoprost/timolol maleate fixed combination from mono- and adjunctive therapies. J Ocul Pharmacol Ther. 2004;20:375-382.

114. Diestelhorst M, Larsson LI. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension. Br J Ophthalmol. 2004; 88:199-203.

115. Konstas AG, Kozobolis VP, Lallos N, et al. Daytime diurnal curve comparison between the fixed combinations of latanoprost 0.005%/timolol maleate 0.5% and dorzolamide 2%/timolol maleate 0.5%. Eye. 2004;18:1264-1269.

116. Shin DH, Feldman RM, Sheu WP. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Ophthalmology. 2004;111:276-282.

117. Gandolfi S, Simmons ST, Sturm R, et al. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 2001;18:110-121.

This page intentionally left blank

Blood Pressure Health

Blood Pressure Health

Your heart pumps blood throughout your body using a network of tubing called arteries and capillaries which return the blood back to your heart via your veins. Blood pressure is the force of the blood pushing against the walls of your arteries as your heart beats.Learn more...

Get My Free Ebook

Post a comment